FDA tells Pharma not to fret about proving PCSK9 inhibitors reduce heart attacks

The FDA tried to ease the concerns of drugmakers Thursday when it said that companies working on a new class of cholesterol-lowering drugs known as PCSK9 inhibitors, may not have to prove they also reduce the risks or heart attacks and strokes. The industry got concerned after two medical groups this week put out new guidelines suggesting doctors drop their emphasis on specific targets for lowering "bad" LDL cholesterol levels and focus also on using drugs that cut their risks for heart attack and stroke. Story | More

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.